Antiretroviral therapy improves TB treatment outcomes among HIV-infected individuals with active pulmonary TB. Individuals not receiving ART benefit from daily rifamycin dosing during the intensive phase of TB treatment and ≥8 months of rifamycin therapy.
Tuberculosis (TB) remains the most common opportunistic infection and cause of death among HIV-infected individuals worldwide. The World Health Organization currently recommends that HIV-infected patients with active TB receive rifamycin for ≥6 months, with daily dosing during at least the intensive phase of TB treatment, and concurrent antiretroviral therapy (ART). A recent systematic review and meta-analysis supports these recommendations and provides further insight into the optimal treatment of active TB in HIV-infected patients.
The review included 33 studies, 7 of which were published between January 2008 and November 2011 (1 randomized, controlled trial and 6 observational TB treatment studies). In multivariate meta-regression analyse…
Reviewing Authors
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)